In the current international general guidelines, intra aortic balloon pump is considered to be the 1 stage of acute myocardial infarction in patients with acute myocardial infarction. However, evidence supporting this theory is only based on the registration data, but also the lack of randomized clinical trials to confirm.

Thiele Holger, PhD, of the German Leipzig medical center, et al, confirmed that patients with acute myocardial infarction who were planning to do a reconstruction of cardiac shock, and that of the patients with acute myocardial infarction, were not significantly reduced by 30 days. The paper is published in the August 27, 2012 online edition of the international authority of the Journal NEJM.
This randomized, prospective, open label, multicenter trial, the researchers randomly assigned 600 patients with acute myocardial infarction (AMI) received intra aortic balloon pump (IABP, 301 patients) or not treated with intra aortic balloon pump (right). 299 patients). All patients were required to undergo early revascularization (percutaneous coronary intervention or bypass surgery) and received the most appropriate therapy. The primary endpoint was 30 day all-cause mortality. Safety assessment included major bleeding, peripheral ischemic complications, sepsis, and stroke.
The results showed that there were 300 patients in the IABP group, and 298 patients in the control group were included in the primary analysis. At 30 days, the IABP group had 119 patients (39.7%), and 123 patients (41.3%) died in the control group (), 0.96; 95% confidence interval, 0.79 to 1.17; P=0.69). Secondary end points or in the course of nursing measures, including time to hemodynamically stable, intensive care time, serum lactate levels, catecholamine treatment dose and duration, and renal function showed no significant between group differences. The major bleeding events in the IABP group and control group were 3.3% and 4.4% (P=0.51), 0.7% and 3.4% (), and and (1.7% and 20.5%, P=0.28), and there was no significant difference in the incidence of sepsis (15.7% P=0.53 4.3%, P=0.15).
The researchers conclude that, for patients with acute myocardial infarction who are planning to carry out the revascularization of patients with cardiac shock, intra aortic balloon pump can not significantly reduce the mortality of 30 days.